Company intelligence / Profile preview

Japan Medical Device Technology

Mashiki-machi, Kumamoto, Japan

Ownership: Private
Development stage: Other

Overview

JMDT develops a magnesium-alloy bioresorbable, sirolimus-eluting coronary stent that has advanced to a first‑in‑human clinical trial in Japan, reportedly the only bioresorbable stent in the country to reach FIH status at the time of the Kaneka acquisition announcement.[3]

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Kaneka (strategic/parent-company collaboration in coronary stents and bioresorbable stents)

Beyond the preview

Go deeper on Japan Medical Device Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Japan Medical Device Technology.

Explore the full profile